Opinion|Videos|November 24, 2025
The Role of BRAF Inhibition in CNS Malignancies
Author(s)Patrick Y. Wen, MD, Karisa C. Schreck, MD, PhD
Patrick Y. Wen, MD, and Karisa C. Schreck, MD, PhD, discuss the use of BRAF inhibitors in the treatment of patients with central nervous system malignanices.
Advertisement
Episodes in this series
Patrick Y. Wen, MD, and Karisa C. Schreck, MD, PhD, discuss the use of BRAF inhibitors in the treatment of patients with central nervous system malignanices.
Advertisement
Related to this article
Readers share their opinions on some of the most talked-about breast cancer abstracts they’re looking forward to seeing at ESMO 2026.
The FDA granted fast track designation to opamtistomig for first-line treatment of advanced or metastatic biliary tract cancer.
Roswell Park Comprehensive Cancer Center has earned national recognition in 2026 from the American Medical Association as a Joy in Medicine organization.
A planned interim analysis of the radiopharmaceutical RYZ101 showed improved PFS by blinded independent central review vs standard of care.
Conditional approvals in Armenia cover botensilimab plus balstilimab indicated for patients with MSS mCRC without active liver metastases.
The top 5 OncLive TV videos of the week.
Check out this September recap of OncLive’s coverage of the top news and expert insights in gastrointestinal cancers.
The FDA approved atezolizumab plus chemo for stage III colon cancer, cleared a tucatinib-based maintenance regimen for advanced breast cancer, and more.
Advertisement
Advertisement
Trending on OncLive
1
Dr Fradley on Real-World Atrial Fibrillation and Cardiovascular Outcomes in CLL
2
Armenia Grants First Marketing Authorizations to Botensilimab Plus Balstilimab in Previously Treated MSS mCRC
3
RYZ101 Meets Primary PFS End Point in Phase 3 ACTION-1 Trial for Post–Lutetium-177 GEP-NETs
4
Poll Results Highlight Breast Cancer Abstracts of Interest at ESMO 2026
5